The poloxamer 407-induced hyperlipidemic atherogenic animal model

Medicine and Science in Sports and Exercise

Volumn 29, Issue 11, 1997, Pages 1416-1421

  Palmer, Warren K ^a   Emeson, Eugene E ^a   Johnston, Thomas P ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Aortic lesions; Hypercholesterolemia; Hypertriglyceridema

Indexed keywords

CHOLESTEROL; CHOLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LOW DENSITY LIPOPROTEIN; POLOXAMER; TRIACYLGLYCEROL;

ANIMAL MODEL; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DIETARY INTAKE; ENZYME ACTIVITY; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; NONHUMAN; RAT; REVIEW;

ANIMALS; ARTERIOSCLEROSIS; CHOLESTEROL; DIET; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERLIPIDEMIAS; INJECTIONS, INTRAVENOUS; MICE; MICE, INBRED C57BL; POLOXALENE; RATS;

EID: 0030733452     PISSN: 01959131     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005768-199711000-00005     Document Type: Review

References (33)

1. BRESLOW, J. B. Mouse models of atherosclerosis. Science 272:685-688, 1996.
2. 2 receptor agonists in rats. Agents Actions 20:255-257, 1987.
3. CHAJEK-SHAUL, T., G. FRIEDMAN, O. STEIN, E. SHILONI, J. ETIENNE, and Y. STEIN. Mechanism of the hypertriglyceridemia induced by tumor necrosis factor administration to rats. Biochim. Biophys. Acta 1001:316-324, 1989.
4. CHO, B., T. SMITH, J. PARK, and F. KUMMEROW. Effects of estrogen-induced hyperlipidemia on the erythrocyte membrane in chicks. Lipids 23:853-856, 1988.
5. EMESON, E. and M. SHEN. Accelerated atherosclerosis in hyperlipidemic C57BL/6 mice treated with cyclosporin A. Am. J. Path. 142:1906-1915, 1993.
6. FRASER, R., S. CLARK, W. DAY, and F. MURRY. Nicotine decreases porosity of the rat liver sieve: A possible mechanism for hypercholesterolemia. Br. J. Exper. Pathol. 69:345-350, 1988.
7. GARCIA-SANIZ, J., J. JUAREZ-AYALA, and V. VALLES. Pertussis toxin induces fatty liver, hyperlipidemia and ketosis in hamsters. Toxicon 25:603-609, 1987.
8. GUSTAFSON, S., C. VAHLQUIST, L. SJÖBLOM, A. EKLUND, and A. VAHLQUIST. Metabolism of very low density lipoproteins in rats with isotretinoin (13-cis retinoic acid) - induced hyperlipidemia. J. Lipid. Res. 31:183-190, 1990.
9. GOLDFARB, S. Rapid increase in hepatic HMG CoA reductase activity and in vivo cholesterol synthesis after Triton WR 1339 injection. J. Lipid. Res. 19:489-494, 1978.
10. ISHIDA, B. Y. and B. PAIGEN. Atherosclerosis in the mouse. In: Genetic Factors in Atherosclerosis: Approaches and Model Systems. A. Lusis and S. Sparkes (eds.). Basel: Karger, pp. 189-222. 1989.
11. ISHIBASHI, S., J. L. GOLDSTEIN, M. S. BROWN, J. HERZ, and D. K. BURNS. Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. J. Clin. Invest. 93:1885-1893, 1994.
12. JOHNSTON, T. P. and W. K. PALMER. The effect of pravastatin on hepatic 3-hydroxy-3-methylglutaryl CoA reductase obtained from poloxamer 407-induced hyperlipidemic rats. Pharmacotherapy 17:342-347, 1997.
13. JOHNSTON, T. P. and W. K. PALMER. Mechanism of poloxamer 407-induced hypertriglyceridemia in the rat. Biochem. Pharmacol. 46:1037-1042, 1993.
14. JOHNSTON, T. P. and W. K. PALMER. Effect of poloxamer 407 on the activity of microsomal 3-hydroxy-3-methylglutaryl CoA reductase in rats. J. Cardiovasc. Pharmacol. 29:580-585, 1997.
15. JOHNSTON, T. P., M. A. PUNJABI, and C. J. FROELICH. Sustained delivery of interleukin-2 from a poloxamer-407 gel matrix following intraperitoneal injection in mice. Pharm. Res. 9:425-434, 1992.
16. KURODA, M., K. TANZAWA, Y. TSUJITA, and A. ENDO. Mechanism for elevation of hepatic cholesterol synthesis and serum cholesterol levels in Triton WR-1339-induced hyperlipidemia. Biochim. Biophys. Acta 489:119-123, 1977.
17. LAURMAN, W. and T. WROUSKA-NOFER. Serum lipid and lipoprotein-cholesterol in rats jointly exposed to carbon disulfide and ethanol. Med. Pr. 37:337-341, 1986.
18. LI, C., W. K. PALMER, and T. P. JOHNSTON. Disposition of poloxamer 407 in rats following a single intraperitoneal injection using a simplified colorimetic assay. J. Pharmaceut. Biomed. Anal. 14:659-665, 1996.
19. LIAO, F., A. ANDALIBI, F. C. DEBEER, A. M FOGELMAN, and A. LUSIS. Genetic control of inflammatory gene induction and NF-KB-like transcription factor activation in response to an atherogenic diet in mice. J. Clin. Invest. 91:2572-2579, 1993.
20. NASH, V. J., T. P. JOHNSTON, and W. K. PALMER. Effects of nicotinic acid on poloxamer 407-induced hyperlipidemia. Phamacotherapy 16:10-15, 1996.
21. NUTTING, D. F. and P. TSO. Hypolipidemic effect of intravenous pluronic L-81 in fasted rats with Triton WR-1339: possible inhibition of hepatic lipoprotein secretion. Horm. Metab. Res. 21:113-115, 1989.
22. ODA, H., N. MATSUSHITA, A. HIRABAYASHI, and A. YOSHIDA. Hyperlipoproteinemia in rats fed polychlorinated biphenyls. J. Nutr. Sci. Vitaminol. 36:117-122, 1990.
23. OHGOCHI, S. H. ICHIMYA, A. YAGI, H. HAYASHI, and N. SAKAMOTO. Copper-induced hypercholesterolemia in golden hamsters: enhanced synthesis of cholesterol in livers. Gastroenterol. Jpn. 23:629-632, 1988.
24. PORTER, J. A., B. L. CARTER, T. P. JOHNSTON, and W. K. PALMER. Effects of pravastatin on plasma lipid concentrations in poloxamer 407-induced hyperlipidemic rats. Pharmacotherapy 15:92-98, 1995.
25. PEC, E. A., Z. G. WOUT, and T. P. JOHNSTON. Biological activity of unease formulated in poloxamer-407 after intraperitoneal injection in the rat. J. Pharm. Sci. 81:626-630, 1992.
26. PAIGEN, B., A. MORROW, P. HOLMES, D. MITCHELL, and R. WILLIAMS. Quantitative assessment of atherosclerotic lesions in the mice. Atherosclerosis 68:231-240, 1987.
27. RAPACZ, J. and J. HASLER-RAPACZ. Animal models: the pig. In: Genetic Factors in Atherosclerosis: Approaches and Model Systems. A. Lusis and S. Sparkes (Eds.). Basel: Karger, pp. 139-169. 1989.
28. SHEFERS, S., L. B. NGUYEN, G. SALEN, et al. Differing effects of cholesterol and taurocholate on steady state hepatic HMG CoA reductase and cholesterol 7α-hydroxylase activities and mRNA levels in the rat. J. Lipid Res. 33:1193-1200, 1992.
29. SHEPHERD, J. and C. J. PACKARD. Pharmacological approaches to the modulation of plasma cholesterol. Trends Pharmacol. Sci. 9:326-329, 1988.
30. STEINLEITNER, A., H. LAMBERT, C. KAZENSKY. and B. CANTOR. Poloxamer-407 as an intraperitoneal barrier material for the prevention of postsurgical adhesion formation and reformation in rodent models for reproductive surgery. Obstet. Gynecol. 77:48-52, 1991.
31. TERCYAK, A. M. and T. E. FELKER. Colorimetric assay for pluronic F-68 as measured in isolated rat liver perfusion systems. Anal. Biochem. 187:54-55, 1990.
32. VAN LENTEN, B. J. Animal models: The Watanabe heritable hyperlipidemic rabbit. In: Genetic Factors in Athersclerosis: Approaches and Model Systems. A. Lusis and S. Sparkes (Eds.). Basel: Karger, pp. 125-138, 1989.
33. WOUT, Z., A. PEC, J. MAGGIORE, R. WILLIAMS, P. PALICHARLA, and T. P. JOHNSTON. POLOXAMER 407-MEDIATED changes in plasma cholesterol and triglycerides following intraperitoneal injections to rats. J. Parenter. Sci. Technol. 46:192-200, 1992.